InflaRx N.V. (IFRX) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 20-F, InflaRx N.V.'s filing signal turned negative.

InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics by targeting the complement system, specifically C5a and its receptor C5aR. The company's lead product candidates are vilobelimab, an intravenously delivered anti-C5a monoclonal antibody, and izicopan, an orally administered small-molecule inhibitor of C5aR1. Vilobelimab has received Emergency Use Authorization (EUA) from the FDA for critically ill COVID-19 patients and marketing authorization in Europe for ARDS. Izicopan is in clinical development for hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU), with promising early-stage data. The company's strategy prioritizes izicopan's development, aiming to address a broad range of autoimmune and inflammatory diseases.

Revenue is primarily generated from product sales of GOHIBIC (vilobelimab), though sales have been minimal and commercialization efforts have been significantly reduced. Future revenue is expected to be driven by the successful development and commercialization of its product candidates, particularly izicopan.